Tajikistan Medical Device Regulation 2026: Not an EAEU Member, a Single National-Track Pathway
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
Tajikistan is neither a member of the Eurasian Economic Union nor has it obtained observer status. This determines that for Chinese manufacturers, market access for medical devices in Tajikistan has only one pathway: the national track. There is no union-track option — the number of union-track channels is 0 and the number of available pathways is 1. A fact that GRZAN repeatedly confirms when serving clients is that a union-track registration certificate valid in the 5 member states of Russia, Belarus, Kazakhstan, Kyrgyzstan and Armenia carries no mandatory market-access effect at Tajik border checkpoints: an enterprise cannot clear customs with it, cannot warehouse goods with it, and cannot sell products or put them into clinical use on its basis.
This conclusion is not our inference but an official public statement by the Tajik side. At the press conference summarizing the Ministry of Foreign Affairs work for 2025 held in Dushanbe, Tajik Foreign Minister Mukhriddin stated that the country has no plans to join the Eurasian Economic Union or BRICS and is not considering participation in these organizations as an observer; he emphasized that Tajikistan maintains close cooperation with all member states of these organizations under bilateral frameworks. Tajik Minister of Economic Development and Trade Zavqizoda previously explained that an interdepartmental working group composed of representatives from government economic bodies, the Ministry of Justice, and the customs and tax committees is analyzing the accession issue and will submit conclusions and recommendations, but no timetable has been given.
2. Legal basis
| Item | Content |
|---|---|
| Legal basis | Law of the Republic of Tajikistan No. 1893 of July 19, 2022, On Medicines, Medical Goods and Pharmaceutical Activity (repromulgated by Law No. 2181 of May 14, 2025) |
| Core provision | Article 17(1): the production, sale and use of medicines and medical goods within the territory of Tajikistan are carried out after state registration has been completed under the procedure determined by the authorized state body in the healthcare sphere |
| Official statement | Statement by the Minister of Foreign Affairs of Tajikistan on February 7, 2026 at the annual work summary press conference of the Ministry of Foreign Affairs in Dushanbe |
| Third-party government source | US Department of State, 2026 Investment Climate Statement for Tajikistan (September 2026): Tajikistan is not a member of the Eurasian Economic Union and therefore not a party to its trade agreements; despite significant pressure from Moscow, the Tajik government has not expressed a desire to join |
| Supplementary | Article 3: this Law applies to natural persons and legal entities engaged in the circulation of medicines, medical goods and parapharmaceuticals, as well as to designated products |
It should be noted together with this that Article 17(1) of Law No. 1893 writes the prerequisite of state registration as the sole gateway: all three actions — production, sale and use — are premised on the completion of state registration. This forms a fundamental difference from the structure in union member states where the national track and the union track operate in parallel.
3. Expert insights
Insight 1: Market access design across the five Central Asian states must be handled in four categories and cannot be copied from one to another. Kazakhstan and Kyrgyzstan are full member states, where manufacturers can choose between the national track and the union track; Uzbekistan is an observer state with only the national track but a regulatory system that closely references the union; Tajikistan and Turkmenistan are outside the union framework and are handled entirely under national procedures. GRZAN performs this status determination first in project scheduling, because all subsequent pathway design, the permissible scope of document reuse, and the customs clearance document list all branch from this point.
Insight 2: The existence of an interdepartmental working group is not a timetable. The Tajik side has continuously studied the feasibility of accession since 2015, and the timing for submission of the working group conclusions remains undetermined. The recommendation of GRZAN is to plan Tajikistan registrations on the assumption that nothing will change within ten years. Treat the five-year validity of the registration certificate and the single re-registration after five years as certainties, and treat union mutual recognition as a variable that should not be built into the business model. Any investment calculation premised on Tajikistan soon joining the union carries structural risk.
Insight 3: The production, sale and use in Article 17(1) are parallel elements, not a progressive sequence. The occurrence of any one of these three actions is premised on completed registration. What is easily overlooked in practice is use — prototype deployment, clinical trials, and academic demonstrations, as long as they constitute use, require item-by-item comparison against the exemption list in Article 26(8), rather than the assumption that no sale means no registration is needed.
4. Practical recommendations
- Segment legal status first in any market matrix before discussing document reuse. A union-track certificate already obtained for Kazakhstan or Kyrgyzstan cannot be directly converted in Tajikistan, but the technical documentation, quality system evidence and clinical data within it can still be used as source material for the Tajikistan registration dossier.
- Write the non-union-member status on the first page of the internal compliance manual. Customs brokers, local distributors and regional sales teams make the most errors at this point — they know the Kazakh rules and tend to treat a union certificate as a regional pass.
- Maintain a separate certificate ledger for Tajikistan. Unlike union markets, a Tajikistan registration certificate requires one full re-registration after the five-year validity expires; the ledger should record both the expiry date and the planned re-registration start date.
- Continuously track the conclusions of the interdepartmental working group. GRZAN monitors this issue through official Tajik news agencies and government meeting communiques; once substantive progress appears, the registration strategy must switch from purely national track to dual-track assessment, and observation indicators for that switch point are worth setting up in advance.
5. Verification checklist
- □ Confirmed the legal status of the target country within the Eurasian Economic Union (Tajikistan: non-member, non-observer)
- □ Confirmed there is no union-track registration certificate on which reliance can be placed
- □ Confirmed under Article 17(1) that production, sale and use are all premised on state registration
- □ Marked Tajikistan as a purely national-track market in the internal compliance manual
- □ Established an independent ledger for Tajikistan registration certificates recording the five-year expiry date
- □ Assessed whether prototype deployment, clinical trials and academic demonstrations fall under the Article 26(8) exemption list
- □ Verified the current version of Law No. 1893 through the ADLIA (MMIH) legal database or the National Center for Legislation under the President
Regulatory information verified as of October 29, 2026.
In the Central Asian market, the core capabilities of GRZAN concentrate on three points: first, distinguishing the different legal status of each market within the Eurasian Economic Union — Kazakhstan and Kyrgyzstan are full member states offering a dual choice between the national track and the union track; Uzbekistan is an observer state with only the national track; Tajikistan and Turkmenistan are outside the union framework and must follow purely national procedures. Second, local authorized representative services, acting as the statutory representative of manufacturers in these countries and undertaking registration submission, regulatory communication and post-market reporting obligations. Third, quality system and testing support, assisting in establishing a quality management system that meets ISO 13485 requirements and connecting with locally accredited laboratory resources.
Business inquiries: info@grzanglobal.com
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us